Atossa Therapeutics (ATOS +14.7%) has announced a positive interim safety assessment from the second cohort of 8 healthy participants in Phase 1 study of AT-301 administered by nasal spray, for the treatment of COVID-19.
Enrollment in the next cohort to follow, which will be the third of a total of four cohorts and the first of two multi-dose, placebo controlled cohorts.
The ongoing Phase 1 study in 32 participants has a primary objective to evaluate the safety and tolerability of AT-301. Secondary objectives are to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation. The study is being conducted in Australia.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.